Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer's disease mice
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Neuronal mitochondrial dysfunction caused by excessive reactive oxygen species (ROS) is an early event of sporadic Alzheimer's disease (AD), and considered to be a key pathologic factor in the progression of AD. The targeted delivery of the antioxidants to mitochondria of injured neurons in brain is a promising therapeutic strategy for AD. A safe and effective drug delivery system (DDS) which is able to cross the blood-brain barrier (BBB) and target neuronal mitochondria is necessary. Recently, bioactive materials-based DDS has been widely investigated for the treatment of AD. Herein, we developed macrophage (MA) membrane-coated solid lipid nanoparticles (SLNs) by attaching rabies virus glycoprotein (RVG29) and triphenylphosphine cation (TPP) molecules to the surface of MA membrane (RVG/TPP-MASLNs) for functional antioxidant delivery to neuronal mitochondria. According to the results, MA membranes camouflaged the SLNs from being eliminated by RES-rich organs by inheriting the immunological characteristics of macrophages. The unique properties of the DDS after decoration with RVG29 on the surface was demonstrated by the ability to cross the BBB and the selective targeting to neurons. After entering the neurons in CNS, TPP further lead the DDS to mitochondria driven by electric charge. The Genistein (GS)- encapsulated DDS (RVG/TPP-MASLNs-GS) exhibited the most favorable effects on reliveing AD symptoms in vitro and in vivo by the synergies gained from the combination of MA membranes, RVG29 and TPP. These results demonstrated a promising therapeutic candidate for delaying the progression of AD via neuronal mitochondria-targeted delivery by the designed biomimetic nanosystems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591
Transvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
Yao, J., Irwin, R. W., Zhao, L., Nilsen, J., Hamilton, R. T., & Brinton, R. D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903563106 · Cited by 940
Mitochondria and Mitochondrial Cascades in Alzheimer’s disease
Swerdlow, R. H. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170585 · Cited by 850
The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786
A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease
Swerdlow, R. H., & Khan, S. M. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2003.12.045 · Cited by 758 · cited 1×
“Previous studies have also shown that ROS-caused oxidative stress not only acts as an inducer but also possesses a sustaining factor in AD [46].”
BackgroundSirtuin regulation of mitochondria: energy production, apoptosis, and signaling
Verdin, E., Hirschey, M. D., Finley, L. W. S., & Haigis, M. C. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.07.003 · Cited by 661
Omidi, Y., Campbell, L., Barar, J., Connell, D., Akhtar, S., & Gumbleton, M. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03443-7 · Cited by 246
HT22 hippocampal neuronal cell line possesses functional cholinergic properties
Liu, J., Li, L., & Suo, W. Z. (2009) · Life Sciences · doi:10.1016/j.lfs.2008.12.008 · Cited by 223
Role of mitochondrial homeostasis and dynamics in Alzheimer's disease
Selfridge, J. E., E, L., Lu, J., & Swerdlow, R. H. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.057 · Cited by 175
Microglial Malfunction: The Third Rail in the Development of Alzheimer's Disease
Mhatre, S. D., Tsai, C. A., Rubin, A. J., James, M. L., & Andreasson, K. I. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.08.006 · Cited by 134
Macrophages Offer A Paradigm Switch for CNS Delivery of Therapeutic Proteins
Klyachko, N. L., Haney, M. J., Zhao, Y., Manickam, D. S., Mahajan, V., Suresh, P., Hingtgen, S. D., Mosley, R. L., Gendelman, H. E., Kabanov, A. V., et al. (2014) · Nanomedicine · doi:10.2217/nnm.13.115 · Cited by 92
Research works printed but not linked: 39
- Keil, 2006, Mitochondrial dysfunction induced by disease relevant A beta PP and tau protein mutations, J. Alzheim. Dis., 9, 139, 10.3233/JAD-2006-9206 · DOI · Paper page
- Pratico, 2008, Evidence of oxidative stress in alzheimer's disease brain and antioxidant therapy lights and shadows, Mitochondria Oxidative Stress Neurodegen. Disord., 1147, 70
- Pacelli, 2015, Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons, Curr. Biol., 25, 2349, 10.1016/j.cub.2015.07.050 · DOI · Paper page
- Du, 2010, Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model, Proc. Natl. Acad. Sci. U.S.A., 107, 18670, 10.1073/pnas.1006586107 · DOI · Paper page
- Battogtokh, 2018, Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives, Acta Pharm. Sin. B, 8, 862, 10.1016/j.apsb.2018.05.006 · DOI · Paper page
- Han, 2020, Neuronal mitochondria-targeted therapy for Alzheimer's disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems, Drug Deliv., 27, 502, 10.1080/10717544.2020.1745328 · DOI · Paper page
- Yang, 2020, Neuronal mitochondria-targeted micelles relieving oxidative stress for delayed progression of Alzheimer's disease, Biomaterials, 238, 10.1016/j.biomaterials.2020.119844 · DOI · Paper page
- Zeng, 2004, Genistein ameliorates beta-amyloid peptide (25-35)-induced hippocampal neuronal apoptosis, Free Radical Biol. Med., 36, 180, 10.1016/j.freeradbiomed.2003.10.018 · DOI
- Kohara, 2015, Genistein improves spatial learning and memory in male rats with elevated glucose level during memory consolidation, Physiol. Behav., 140, 15, 10.1016/j.physbeh.2014.12.005 · DOI
- Wu, 2010, Solubility of genistein in water, methanol, ethanol, propan-2-ol, 1-butanol, and ethyl acetate from (280 to 333) K, J. Chem. Eng. Data, 55, 5286, 10.1021/je100261w · DOI
- Zhou, 2008, Dose-dependent absorption, metabolism, and excretion of genistein in rats, J. Agric. Food Chem., 56, 8354, 10.1021/jf801051d · DOI
- Kwon, 2016, Mitochondria-targeting Ceria nanoparticles as antioxidants for alzheimer's disease, ACS Nano, 10, 2860, 10.1021/acsnano.5b08045 · DOI · Paper page
- Parodi, 2013, Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions, Nat. Nanotechnol., 8, 61, 10.1038/nnano.2012.212 · DOI · Paper page
- Kroll, 2017, Nanoparticulate delivery of cancer cell membrane elicits multiantigenic antitumor immunity, Adv. Mater., 29, 10.1002/adma.201703969 · DOI · Paper page
- Ma, 2019, Targeted drug delivery to stroke via chemotactic recruitment of nanoparticles coated with membrane of engineered neural stem cells, Small, 15, 10.1002/smll.201902011 · DOI · Paper page
- Fang, 2017, Cell membrane-derived nanomaterials for biomedical applications, Biomaterials, 128, 69, 10.1016/j.biomaterials.2017.02.041 · DOI · Paper page
- Zhao, 2011, Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles, Nanomedicine, 6, 25, 10.2217/nnm.10.129 · DOI · Paper page
- Brynskikh, 2010, Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease, Nanomedicine, 5, 379, 10.2217/nnm.10.7 · DOI · Paper page
- Cao, 2016, Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer, ACS Nano, 10, 7738, 10.1021/acsnano.6b03148 · DOI · Paper page
- Zhang, 2018, Macrophage-membrane-coated nanoparticles for tumor-targeted chemotherapy, Nano Lett., 18, 1908, 10.1021/acs.nanolett.7b05263 · DOI · Paper page
- Fu, 2019, Dual-modified novel biomimetic nanocarriers improve targeting and therapeutic efficacy in glioma, ACS Appl. Mater. Interfaces, 11, 1841, 10.1021/acsami.8b18664 · DOI · Paper page
- Park, 2015, Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer's disease, Biomaterials, 38, 61, 10.1016/j.biomaterials.2014.10.068 · DOI
- Cui, 2019, RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer's disease, Immun. Ageing, 16, 10.1186/s12979-019-0150-2 · DOI · Paper page
- Marrache, 2012, Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics, Proc. Natl. Acad. Sci. U.S.A., 109, 16288, 10.1073/pnas.1210096109 · DOI · Paper page
- Baron-Bodo, 2005, Anti-tumor properties of human-activated macrophages produced in large scale for clinical application, Immunobiology, 210, 267, 10.1016/j.imbio.2005.05.021 · DOI
- Wang, 2015, In vitro model of the blood-brain barrier established by co-culture of primary cerebral microvascular endothelial and astrocyte cells, Neural Regen. Res., 10, 2011, 10.4103/1673-5374.172320 · DOI
- Zhang, 2015, Micellar emulsions composed of mPEG-PCL/MCT as novel nanocarriers for systemic delivery of genistein: a comparative study with micelles, Int. J. Nanomed., 10, 6175
- Wang, 2010, Vanadium compounds discriminate hepatoma and normal hepatic cells by differential regulation of reactive oxygen species, J. Biol. Inorg. Chem., 15, 1087, 10.1007/s00775-010-0668-4 · DOI
- Soucy, 2006, Kinetics of genistein and its conjugated metabolites in pregnant Sprague-Dawley rats following single and repeated genistein administration, Toxicol. Sci., 90, 230, 10.1093/toxsci/kfj077 · DOI
- Yao, 2016, Nanoformulated alpha-mangostin ameliorates Alzheimer's disease neuropathology by elevating LDLR expression and accelerating amyloid-beta clearance, J. Contr. Release, 226, 1, 10.1016/j.jconrel.2016.01.055 · DOI
- Zhao, 2012, Self-assembly nanomicelles based on cationic mPEG-PLA-b-Polyarginine(R-15) triblock copolymer for siRNA delivery, Biomaterials, 33, 6793, 10.1016/j.biomaterials.2012.05.067 · DOI
- Baer, 1990, Rabies susceptibility and acetylcholine-receptor, Lancet, 335, 664, 10.1016/0140-6736(90)90454-D · DOI
- Biswas, 2012, Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo, J. Contr. Release, 159, 393, 10.1016/j.jconrel.2012.01.009 · DOI · Paper page
- Wang, 2016, Mitochondria as a therapeutic target in Alzheimer's disease, Genes Dis., 3, 220, 10.1016/j.gendis.2016.05.001 · DOI · Paper page
- Qian, 2015, Protection by genistein on cortical neurons against oxidative stress injury via inhibition of NF-kappaB, JNK and ERK signaling pathway, Pharm. Biol., 53, 1124, 10.3109/13880209.2014.962057 · DOI
- Zhang, 2013, Edaravone ameliorates oxidative damage associated with A beta 25-35 treatment in PC12 cells, J. Mol. Neurosci., 50, 494, 10.1007/s12031-013-9973-z · DOI
- Greenhalgh, 2020, Immune cell regulation of glia during CNS injury and disease, Nat. Rev. Neurosci., 21, 139, 10.1038/s41583-020-0263-9 · DOI · Paper page
- Hinde, 2017, Pair correlation rnicroscopy reveals the role of nanoparticle shape in intracellular transport and site of drug release, Nat. Nanotechnol., 12, 81, 10.1038/nnano.2016.160 · DOI · Paper page
- Marrache, 2012, Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics, Proc. Natl. Acad. Sci. U.S.A., 109, 16288, 10.1073/pnas.1210096109 · DOI · Paper page
Cited by
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906
“205 The MA membranes provided RVG/TPP-MASLNs with favorable biocompatibility and reticuloen-dothelial system evasion behaviors.”
BackgroundNanoparticles as antimicrobial and antiviral agents: A literature-based perspective study
Sharmin, S., Rahaman, M. M., Sarkar, C., Atolani, O., Islam, M. T., & Adeyemi, O. S. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e06456 · Cited by 338
Wu, Y., Wan, S., Yang, S., Hu, H., Zhang, C., Lai, J., Zhou, J., Chen, W., Tang, X., Luo, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01746-6 · Cited by 301
Nakamura, T., Sato, Y., Yamada, Y., Abd Elwakil, M. M., Kimura, S., Younis, M. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114417 · Cited by 121
Ouyang, Q., Liu, K., Zhu, Q., Deng, H., Le, Y., Ouyang, W., Yan, X., Zhou, W., & Tong, J. (2022) · Small · doi:10.1002/smll.202107534 · Cited by 94
Metadata
- Authors
- Han, Y., Gao, C., Wang, H., Sun, J., Liang, M., Feng, Y., Liu, Q., Fu, S., Cui, L., Gao, C., Li, Y., Yang, Y., & Sun, B.
- Venue
- Bioactive Materials
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 6
- Issue
- 2
- Pages
- 529-542
- ISSN
- 2097-1192 (ISSN-L)
- 2452-199X
- OpenAlex
- W3086867618
- Cited by
- 197
- References
- 12
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Update notices
- erratum (2022-01-01)
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- National Science and Technology Major Projects for Major New Drugs Innovation and Development (2018ZX09711003-008-001)
- Beijing Natural Science Foundation (7172162)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.